Uttroside B

Drug Profile

Uttroside B

Alternative Names: UTTROSIDE-B

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rajiv Gandhi Centre for Biotechnology
  • Class Antineoplastics; Saponins; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase modulators; MTOR protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 21 Dec 2017 Q BioMed plans to file an IND application for Hepatocellular carcinoma
  • 21 Dec 2017 Q BioMed plans a phase I clinical trial for Hepatocellular carcinoma in late 2018
  • 07 Feb 2017 Q BioMed, Rajiv Gandhi Centre for Biotechnology and Oklahoma Medical Research Foundation enter a research collaboration to develop Uttroside B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top